Optimi Health Corp. (OPTH) Form 6-K — Oct 26, 2026

$OPTHForm 6-KFiled Oct 26, 2026, 8:00 AM ET0001171843-26-006808Original filing

Optimi Health Corp. (Nasdaq: OPTH) announced the formation of Optimi Australia Pty Ltd, a wholly owned subsidiary handling sales, distribution, and prescriber relationships across Australia, the company's first commercial market. The subsidiary will sell Optimi's 5mg psilocybin and 40mg/60mg MDMA capsules to clinics and pharmacies under Australia's Authorised Prescriber Scheme, with all products manufactured at the company's Health Canada-licensed GMP facility in British Columbia.

Key figures

Mdma Capsule Dose Mg: [40,60]
Psilocybin Capsule Dose Mg: 5
Years At Bristol Myers Squibb: 15

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.